- Home
- INO vs CLNN Comparison
INO vs CLNN Comparison
Compare INO & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- CLNN
- Stock Information
- Founded
- INO 1979
- CLNN 2012
- Country
- INO United States
- CLNN United States
- Employees
- INO N/A
- CLNN N/A
- Industry
- INO Medical/Dental Instruments
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- INO Health Care
- CLNN Health Care
- Exchange
- INO Nasdaq
- CLNN Nasdaq
- Market Cap
- INO 69.3M
- CLNN 57.9M
- IPO Year
- INO 1998
- CLNN N/A
- Fundamental
- Price
- INO $2.18
- CLNN $6.17
- Analyst Decision
- INO Buy
- CLNN Strong Buy
- Analyst Count
- INO 5
- CLNN 6
- Target Price
- INO $8.80
- CLNN $32.67
- AVG Volume (30 Days)
- INO 2.1M
- CLNN 117.0K
- Earning Date
- INO 11-13-2025
- CLNN 11-12-2025
- Dividend Yield
- INO N/A
- CLNN N/A
- EPS Growth
- INO N/A
- CLNN N/A
- EPS
- INO N/A
- CLNN N/A
- Revenue
- INO $182,337.00
- CLNN $286,000.00
- Revenue This Year
- INO N/A
- CLNN N/A
- Revenue Next Year
- INO $15,960.33
- CLNN $2,178.18
- P/E Ratio
- INO N/A
- CLNN N/A
- Revenue Growth
- INO N/A
- CLNN N/A
- 52 Week Low
- INO $1.30
- CLNN $2.28
- 52 Week High
- INO $7.00
- CLNN $7.10
- Technical
- Relative Strength Index (RSI)
- INO 47.09
- CLNN 59.58
- Support Level
- INO $2.33
- CLNN $5.77
- Resistance Level
- INO $2.98
- CLNN $6.54
- Average True Range (ATR)
- INO 0.20
- CLNN 0.57
- MACD
- INO -0.07
- CLNN -0.04
- Stochastic Oscillator
- INO 2.44
- CLNN 53.03
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.